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Abstract
Smoking has negative effect on most diseases, yet it is under-investigated in people
with epilepsy; thus its role is not clear in the general population with epilepsy. We
performed a retrospective pilot study on males with epilepsy to determine the smoking
rate and its relationship with seizure control using univariate analysis to calculate odds
ratios (ORs) and also used a multi-variate logistic regression model., The smoking rate
in our sample of 278 individuals was 25.5%, which is lower than the general Chinese
population smoking rate amongst males of 52.1%. We used two classifications: the first
classified epilepsy as generalized, or by presumed topographic origin (temporal, frontal,
parietal and occipital). the second classified the individuals dominant seizure type as
generalized tonic clonic seizure (GTCS), myoclonic seizure (MS), complexed partial
seizure (CPS), simple partial seizure (SPS), and secondary GTCS (sGTCS). The
univariable analysis of satisfactory seizure control profile and smoking rate in both
classifications showed a trend towards a beneficial effect of smoking although most
were not statistically significant. Considering medication is an important confounding
factor that would largely influence seizure control, we also conducted multi-variable
analysis for both classifications with drug numbers and dosage. The result of our model
also suggested that smoking is a protective factor. Our findings seem to suggest that
smoking could have a potential role in seizure control although confounders need
exploration particularly in view of the potential long term health effects. Replication in
a much larger sample is needed as well as case control studies to elucidate this issue.
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1. Introduction
Cigarette smoking is a worldwide health problem. Given its high prevalence among the
population, many studies have been done over the years regarding its health effects. In
some diseases, smoking has negative effect, while in others, for example in
inflammatory bowel diseases1,2, it can be a protective factor.
Some aspects of smoking in people with epilepsy have been investigated. Most studies
considered the general prevalence rate of smoking in people with epilepsy rather than
the effect of smoking3-8. In several studies the smoking rates in people with epilepsy
were always higher than in the general population, with rates ranging from 21.8% to
38.8%3-8; the smoking rate in people with epilepsy is also higher than in most other
chronic diseases6. The smoking rate was even higher in people with drug resistant
epilepsy9. A recent study, however, showed the rate was dropping10.
Some reports suggest that smoking can have negative effects on seizures and epilepsy
(ref.). There are studies concluding that children of women who smoke have a higher
rate of febrile seizures11-13, although other studies did not find confirm this14,15. Women
with epilepsy have been shown to have an increased risk of premature contractions and
premature birth16,17. Self-reporting seizure triggering factors suggest that smoking may
be a trigger factor with other factors such as medication withdrawn and sleep
deprivation18. Poor adherence to a medication regime may co-occur in adolescents19. In
a prospective study of a nurse cohort followed for more than 20 years, current cigarette
smoking was associated with an increased risk of seizures (RR 2.60, 95% CI 1.53-4.42),
and past smoking was associated with an increased risk of epilepsy (RR 1.46, 95% CI
1.01-2.12)20. Smoking may also influence drug concentrations in serum. Several studies
suggest that smokers may have lower serum drug concentrations than non-smokers
while taking the same drug (such as lamotrigine (LTG)) due to smoking related hepatic
enzyme changes21. Nicotine, a main component in cigarettes, has also been shown to
lower the seizure threshold in animals22.
Conversely, nicotine has been confirmed as being protective and as having a treatment
effect in rare hereditary epilepsy (autosomal dominant nocturnal frontal lobe epilepsy
[ADNFLE]). The mutated gene in ADNFLE is related to functioning of the nicotinic
acetylcholine receptor. People with epilepsy in families with ADNFLE who smoked or
used nicotine patches had a better overall seizure control than those who do not23.
However, in sporadic nocturnal frontal lobe epilepsy failed to determine the role of
smoking24. Another study showed that nicotine patch use in video EEG monitoring
increased the hospitalization of people with epilepsy as fewer seizure events were
captured25. Thus there is some circumstantial evidence for smoking and nicotine to have
a beneficial effect on seizure control.
Data from 2015, suggest that the general smoking rate in the Chinese population is
27.7%, (52.1% in males and 2.7% in females)26. Smoking rates amongst people with
epilepsy in China has not been recently ascertained. We aimed to investigate the role of
smoking in people with epilepsy in China.
2. Materials and methods
We have an established clinical databank for people with epilepsy in our center. The
data bank should include data on all those who routinely attend Data includes contact
information and demographics such as name, sex, age, education profile, marriage
status and number of children. Recorded clinical data includes diagnosis, EEG,
neuroimaging, seizure types, current seizure frequency, medication profile and epilepsy
phase (table 1).
Table 1. Definition of different phases of an individual with epilepsy
Active phase Individuals have had a seizure within the
previous year and are changing their
medication
Maintenance phase a. Seizures have stopped and no
medication changes have taken place
within the previous year (Type 1)
b. Individuals have had a seizure within
the previous year but have had no
medication change (Type 2)
Medication reducing phase Individuals reducing their medications
No medication phase Individuals who have reduced and
subsequently stopped their medications
The establishment of the databank was approved by West China Hospital Ethics
Committee and written consent is always provided by individuals before data collected.
In November 2015, we contacted by telephone males in the databank inquiring about
their smoking status (as below). Only those in the databank prior to November 2014
were contacted as to avoid including individuals with newly diagnosed epilepsy. Only
males were included in this pilot study as most smokers in China are males. We
excluded people with a history of poor adherence and those whose final diagnosis was
not epilepsy. We also excluded newly diagnosed patients (hard to evaluate their seizure
control in a short time) and symptomatic epilepsy.
We collected data on smoking status as – never-smoker, current smoker (at least 1
cigarette per day in past 6 months), former smoker (smoking stopped by the time of the
study). For smokers and former smokers were recorded number of years smoking. We
also performed the Fagerström Test of Nicotine Dependence (FTND) on the current
smokers27. This includes 6 questions, and we calculated the nicotine dependence level
of individuals by adding the grade of all items together. Smokers with a total grade
lower than 6 were considered as having a low to moderate nicotine dependence level
and those with grade equal or higher than 6 were considered as having a high nicotine
dependence level.
2.1 Epilepsy classification
Individuals were classified based on clinical judgement as having focal or generalized
epilepsy, and by the dominant seizure type. Focal or generalized epilepsy included
categories such as temporal lobe epilepsy, frontal lobe epilepsy, parietal lobe epilepsy,
occipital lobe epilepsy and generalized epilepsy. For dominant seizure types,
individuals were grouped as having generalized tonic clonic seizures (GTCS),
myoclonic seizures (MS), simple partial seizures (SPS), complexed partial seizures
(CPS) and secondarily generalized tonic clonic seizure (sGTCS).
2.2 Smoking rate and seizure control
For simplicity, we classified seizure control profile into satisfactory seizure control and
unsatisfactory seizure control. We excluded individuals in the Type 2 maintenance
phase who had seizures within a year without medication change because the reasons
for not changing their medication were complicated. They may be less affected by their
seizures and decided not to increase dose of medication or they could have drug
resistant epilepsy or they may be having seizures frequently but refused to take more
medication for worrying side effects. These two situations couldn’t be considered
neither as satisfied nor unsatisfied seizure control. So satisfactory seizure control was
defined as type 1 maintenance phase, reduced medication phase and no medication.
Unsatisfactory seizure control was defined as being in the active phase.
All our data was processed in SAS version 9.4 (SAS Institute, Cary, NC, USA). The
smoking rate was calculated based on the whole cohort and both classifications. For
different categories within a classification, we also compared the difference of smoking
rate by chi-square to establish whether smoking rate is different between categories.
The seizure control profile under each category of classification was compared by
calculation of odds ratios [OR]). For example, in temporal lobe epilepsy using the focal
or generalized epilepsy classification, we calculated the number of individuals who
smoke with satisfactory seizure control, those who smoke with unsatisfactory seizure
control, those who do not smoke with satisfactory seizure control and those who do not
smoke with unsatisfactory seizure control, thus we can generate an OR and also identify
its statistical significance. We did the same for all categories in 2 different classification
systems.
2.3 Multi-variable analysis for smoking and epilepsy
The control profile in an individual is primarily based on anti-epileptic drugs (AEDs),
thus medications were considered as confounding factors in our analysis. We simply
categorized the number of medications as equal or less than 2 medications and more
than 2 medications. Furthermore, we considered comparative dosage of their
medications as small or large dosage using definition of daily drug dosage (DDD)
among different AEDs by WHO.
Table 2. Definition of small and large dosage for a patient based on medication number and
dosage for each medication
Small dosage Large dosage
Only 1 medication ≤50%DDD ＞50%DDD
2 medications a. Both≤50%DDD
b. 1≤50%DDD
a. Both＞50% DDD
3 medications a. All≤50% DDD
b. 1＞50% DDD
other 2 ≤50%DDD
a. 2＞50% DDD
b. All＞50%DDD
4 medications a. All≤50%DDD
b. 1＞50%DDD,
other≤50%DDD
c. 2＞50%DDD,
other 2≤50%DDD
a. 3＞50%DDD,
1≤50%DDD
b. All＞50%DDD
We performed multiple logistic regression analysis model based on medication
numbers, dosage levels, age of the patient (between different age of patients, the
smoking rate can be different), their smoking status as yes or no and separately using
both classification methods. We calculated the coefficients and evaluated whether
smoking is a protective factor for seizure control in people with epilepsy.
2.4 Dependence level of nicotine and seizure control
For smokers, we also analyzed their nicotine dependence level as low or high and
explored its relationship with seizure control. We performed Chi square test to identify
whether the dependence level on nicotine could affect seizure control profile. If the
expected frequency bigger than 1 but lower than 5, Yate’s correction will be done for
the small sample size.
3. Results
3.1 Prevalence of smoking in people with epilepsy
a. General data of our cohort and smoking prevalence
Among 1000 individuals we reviewed in our data bank, 342 were males and met our
inclusion criteria; 64 were further excluded as we were unable to contact them. Only 2
(0.72%) individuals stopped smoking (they all quitted more than 5 years) among the
278 we included in our analysis; 71 (25.5%) were current smokers. Thus the prevalence
of smoking among males with epilepsy in our cohort is 25.5%, while among general
adult males in China it is 52%.
In our cohort, 70 people (25.2%) had temporal lobe epilepsy, 41 (14.75%) had frontal
lobe epilepsy, two had parietal lobe epilepsy, one had occipital lobe epilepsy and 164
(59%) had generalized epilepsy. Regarding the dominant seizure type, 218 (78.4%) had
GTCS, two had MS, 7 had SPS, 42 (15%) had CPS and nine (3.2%) had SGTCS. We
thus excluded those with parietal lobe epilepsy and occipital lobe epilepsy, and those
with MS and SPS, due to their small numbers in our cohort. We simply classified our
patients as smoking and not smoking according to their current smoking status.
b. Different smoking rates among people with different types of epilepsy
Table 3. Smoking rate in focal epilepsies or generalized epilepsy
Not smoking smoking Total Smoking rate Chi-square Test
Temporal lobe epilepsy 40 17 57 29.8%
2 1.9226 
P=0.38
Frontal lobe epilepsy 29 6 35 17.1%
Generalized epilepsy 114 36 150 24.0%
Total 183 59 242 24. 4%
Table 4. Smoking rate according to dominant seizure type
Not smoking Smoking Total Smoking rate Chi-square Test
GTCS 147 47 194 24.2%
2 0.2225 
P=0.89
CPS 27 7 34 20.6%
SGTCS 7 2 9 22.2%
Total 181 56 237 23.6%
The Chi-square test shows no difference in smoking rates among people with different
types of epilepsy.
3.2 Smoking and seizure control
a. Analysis in different origins of epilepsy
Table 5. Seizure control and epilepsy in focal epilepsies or generalized epilepsy
The ORs in temporal lobe epilepsy, frontal lobe epilepsy and generalized epilepsy are
Epilepsy
origin
Control
Profile
Not
smoking
Smoking Total OR 95% CI of OR
Temporal
lobe
Epilepsy
Unsatisfactory 23 4 27
4.3971 1.2176-15.8792Satisfactory 17 13 30
Total 40 17 57
Frontal
Lobe
Epilepsy
Unsatisfactory 12 1 13
3.5294 0.3644-34.1847Satisfactory 17 5 22
Total 29 6 35
Generalized
epilepsy
Unsatisfactory 34 8 42
1.4875 0.6156-3.5943Satisfactory 80 28 108
Total 114 36 150
all higher than 1, suggesting a tendency of smoking to be a protective factor in all three
types of epilepsy; the 95% CIs are wide. In temporal lobe epilepsy the lower confidence
limit of the OR value is higher than 1 suggesting that, in this group, smoking is a
statistically significant protective factor. This analysis, however, does not include
confounders, so we performed multi-variable analyses.
Table 6. Multi-variable analysis for control of seizures in focal or generalized epilepsy
β P value OR 95%CI of OR
Number of drugs
＞2 referent - - -
≤2 1.4788 0.0002 4.388 2.020-9.532
Drug dosage
Large referent - - -
Small 0.5459 0.0726 1.726 0.951-3.132
Epilepsy Origin
Temporal lobe epilepsy referent - -
Frontal lobe epilepsy 0.4141 0.3848 1.513 0.595-3.850
Generalized epilepsy 0.7717 0.0299 2.163 1.078-4.341
Smoking
No referent - -
Yes 0.9016 0.0174 2.463 1.172-5.178
age 0.00243 0.8114 1.002 0.983-1.023
For each factor we listed here, the first line is used as a referent in our analysis. The
goal is satisfactory seizure control profile. Statistically significant OR>1 means
comparing to the referent, the chance of satisfactory seizure control is increased.
Statistically significant OR＜1 means the opposite.
This logistic regression model shows that smoking is a protective factor for seizure
control with OR=2.463（95%CI 1.172-5.178）. Similar to univariate analysis, smoking
is still a protective factor in consideration of different medication profile for patients.
In our model, taking fewer medications is also associated with better seizure control.
We think that’s because fewer drugs mean the seizure respond to medication and is not
drug resistant. Except for fewer medication, generalized epilepsy is related to better
control compared to temporal lobe epilepsy and frontal lobe epilepsy.
Age and drug dosage is not related with seizure control based on our data.
b. Analysis in different dominant types of seizures in epilepsy
We did the same analysis in regard of different types of seizure as a classification for
people with epilepsy.
Table 7. Seizure control and epilepsy in different dominant seizure types
Seizure
type
Control
profile
Not
smoking
Smoking Total OR 95%CI of OR
GTCS
Unsatisfactory 53 10 63
2.0862 0.9607-4.5302Satisfactory 94 37 131
Total 147 47 194
CPS
Unsatisfactory 14 3 17
1.4359 0.2685-7.6777Satisfactory 13 4 17
Total 27 7 34
SGTCS
Unsatisfactory 0 2 2
Not
Applicable
Not
Applicable
Satisfactory 2 5 7
Total 2 7 9
Table 8. Multi-variable analysis for control profile in dominant seizure type based analyzed epilepsy
patients
β P value OR 95%CI of OR
Number of drugs
＞2 referent - - -
≤2 1.4918 0.0001 4.445 2.059-9.595
Drug dosage
Large referent - - -
Small 0.5399 0.0752 1.716 0.947-3.110
Dominant seizure
SGTCS referent - -
CPS -1.0988 0.2457 0.333 0.052-2.130
GTCS -0.5678 0.5177 0.567 0.101-3.166
smoking
No referent - -
Yes 0.8186 0.0307 2.267 1.079-4.764
age -0.00006 0.0105 1.000 0.980-1.021
The result is similar to the other classification. The univariate analysis still shows a
tendency of smoking being a protective factor, but none of the ORs is statistically
significant as we showed before, but the multivariate analysis has a significant OR
=2.267(95%CI 1.079-4,764) for having protective effect compared to no smoking.
3.3 Dependence level of nicotine and seizure control in smoking patients
Table 9. Nicotine dependence level and seizure control
Control
profile
Low dependence High dependence Total Chi-square Test
unsatisfied 8 5 13
2
c 0.0038 
P=0.9507
Satisfied 31 15 46
Total 39 20 59
Since we have showed smoking is a protective factor in both classifications and the
populations are relatively small, we analyzed all individuals as one group to investigate
nicotine dependence level and seizure control; no association was found.
4. Discussion
Our findings suggest smoking rate in Chinese adult males with epilepsy is much lower
than in the general adult male population. Since our study is a retrospective
observational study, our results suggested there is a tendency for smoking and less
seizure frequnency.
There seems to be a relatively low smoking rate among people with epilepsy in China
particularly in males and this seems to be different scenario from that in other countries
in which there seem to be a higher prevalence of smoking amongst people with epilepsy
than in the general population. This may be due to public health campaigns over
emphasizing negative effects of smoking which may led to people assume its negative
role in epilepsy. Different from more developed countries, the Chinese patient-doctor
mode is still more paternal, which means that people tend to follow their physician’s
instructions in their daily life. In recent years, people have been more careful about
their own health because of better life quality. There could also be reasons such as more
opportunities for communication between physicians and patients with all kinds of
social media, and the patients are therefore better educated. This gives us more
responsibility to inform our patients with more accurate information and more evidence
based instruction. It is also possible, particularly in view of the lower prevalence of
smoking in people with epilepsy than in the general population, that people with worse
seizure control may have previously stopped smoking in an attempt to improve their
overall health and, potentially, their seizure control.
Our findings seem to suggest a potential protective role of smoking; the higher
dependence level on nicotine, however, is not related to better overall control in those
who smoke. This may show that smoking/nicotine does not affect the seizure control
profile by its intensity, or that it changes epileptic network in a qualitative way. Whether
the change is stable or stops with smoking cession is unknown. Maybe extract from
cigarette as adjunctive medication or nicotine therapy could help obtain better seizure
control in patients. More studies could also be performed to investigate how smoking
affects the whole epilepsy network in the brain to add for more evidence on this topic.
We also found a slightly (non-significant) higher rate of smoking among people with
temporal lobe epilepsy. This may be related to temporal lobe epilepsy affecting the
emotion of patient, thus individuals may be more anxious or depressed, which could be
a reason for them to smoke. In this way, the emotional network may also affect the
seizure control of an individual, which smoking can act on, and exert its protective
effect, as seen in our study.
Our study is just a pilot study, and it was limited by a small number in some subgroups
and retrospectively. There should be a better designed, more confounders considered
and prospective study to be explored in the future.
Reference
1. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Impact of
cessation of smoking on the course of ulcerative colitis. The American journal of
gastroenterology 2001;96:2113-6.
2. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current
and former cigarette smoking on the clinical course of Crohn's disease. Alimentary
pharmacology & therapeutics 1999;13:1403-11.
3. Cui W, Zack MM, Kobau R, Helmers SL. Health behaviors among people with
epilepsy--results from the 2010 National Health Interview Survey. Epilepsy & behavior :
E&B 2015;44:121-6.
4. Elliott JO, Moore JL, Lu B. Health status and behavioral risk factors among
persons with epilepsy in Ohio based on the 2006 Behavioral Risk Factor Surveillance
System. Epilepsy & behavior : E&B 2008;12:434-44.
5. Ferguson PL, Chiprich J, Smith G, et al. Prevalence of self-reported epilepsy,
health care access, and health behaviors among adults in South Carolina. Epilepsy &
behavior : E&B 2008;13:529-34.
6. Hinnell C, Williams J, Metcalfe A, et al. Health status and health-related behaviors
in epilepsy compared to other chronic conditions--a national population-based study.
Epilepsia 2010;51:853-61.
7. Kobau R, DiIorio CA, Price PH, et al. Prevalence of epilepsy and health status of
adults with epilepsy in Georgia and Tennessee: Behavioral Risk Factor Surveillance
System, 2002. Epilepsy & behavior : E&B 2004;5:358-66.
8. Torriani O, Vuilleumier F, Perneger T, et al. Epilepsy and tobacco smoking: a cross-
sectional study. J Neurol 2016.
9. Hamilton M, McLachlan RS, Burneo JG. Can I go out for a smoke? A nursing
challenge in the epilepsy monitoring unit. Seizure 2009;18:285-7.
10. Roberts JI, Patten SB, Wiebe S, Hemmelgarn BR, Pringsheim T, Jette N. Health-
related behaviors and comorbidities in people with epilepsy: Changes in the past decade.
Epilepsia 2015;56:1973-81.
11. Vestergaard M, Wisborg K, Henriksen TB, Secher NJ, Ostergaard JR, Olsen J.
Prenatal exposure to cigarettes, alcohol, and coffee and the risk for febrile seizures.
Pediatrics 2005;116:1089-94.
12. Berg AT, Shinnar S, Shapiro ED, Salomon ME, Crain EF, Hauser WA. Risk factors
for a first febrile seizure: a matched case-control study. Epilepsia 1995;36:334-41.
13. Nelson KB, Ellenberg JH. Prenatal and perinatal antecedents of febrile seizures.
Ann Neurol 1990;27:127-31.
14. Vahidnia F, Eskenazi B, Jewell N. Maternal smoking, alcohol drinking, and febrile
convulsion. Seizure 2008;17:320-6.
15. Asadi-Pooya AA, Hojabri K. Risk factors for childhood epilepsy: a case-control
study. Epilepsy & behavior : E&B 2005;6:203-6.
16. Harden CL, Hopp J, Ting TY, et al. Management issues for women with epilepsy-
Focus on pregnancy (an evidence-based review): I. Obstetrical complications and
change in seizure frequency: Report of the Quality Standards Subcommittee and
Therapeutics and Technology Assessment Subcommittee of the American Academy of
Neurology and the American Epilepsy Society. Epilepsia 2009;50:1229-36.
17. Hvas CL, Henriksen TB, Ostergaard JR, Dam M. Epilepsy and pregnancy: effect
of antiepileptic drugs and lifestyle on birthweight. Bjog 2000;107:896-902.
18. Balamurugan E, Aggarwal M, Lamba A, Dang N, Tripathi M. Perceived trigger
factors of seizures in persons with epilepsy. Seizure 2013;22:743-7.
19. Kyngas H. Compliance with health regimens of adolescents with epilepsy. Seizure
2000;9:598-604.
20. Dworetzky BA, Bromfield EB, Townsend MK, Kang JH. A prospective study of
smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult
women: data from the Nurses' Health Study II. Epilepsia 2010;51:198-205.
21. Reinsberger C, Dorn T, Kramer G. Smoking reduces serum levels of lamotrigine.
Seizure 2008;17:651-3.
22. Sood N, Hota D, Sahai AK, Chakrabarti A. Nicotine reversal of anticonvulsant
action of topiramate in kainic acid-induced seizure model in mice. Nicotine Tob Res
2011;13:1084-91.
23. Brodtkorb E, Picard F. Tobacco habits modulate autosomal dominant nocturnal
frontal lobe epilepsy. Epilepsy & behavior : E&B 2006;9:515-20.
24. Naldi I, Bisulli F, Vignatelli L, et al. Tobacco habits in nocturnal frontal lobe
epilepsy. Epilepsy & behavior : E&B 2013;26:114-7.
25. Parikh MS, Haltiner AM, de Menezes MS, et al. Nicotine patches--do they
influence seizure number, stay durations or seizure rate during video EEG telemetry?
Epilepsy & behavior : E&B 2012;23:389-91.
26. Report of cigarette consumption of adult Chinese in 2015 Shanghai Journal of
Preventive Medicine, 2015;12.
27. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test
for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British
journal of addiction 1991;86:1119-27.
Appendix
FTND for current smokers
Questions Answers Grade
1. How soon after you
wake up do you
smoke your first
cigarette?
Within 5 mins
6-30 mins
31-60 mins
More than 60 mins
3
2
1
0
2. Do you find it
difficult to refrain
from smoking in
places where it is
forbidden?
Yes
No
1
0
3. Which cigarette
would you hate most
to give up?
First one in morning
Other
1
0
4. How many cigarettes
a day do you smoke?
≤10 
11-20
21-30
＞30
0
1
2
3
5. Do you smoke more
frequently during
the first hours after
waking than during
the rest of the day?
Yes
No
1
0
6. Do you smoke if you
are so ill that you are
in bed most of the
Yes
No
1
0
day?
